A recent phase 2 clinical trial reveals that Ambroxol, a common cough medicine, shows promise in stabilizing psychiatric ...

Ambroxol is commonly used as an expectorant in cough syrup, helping thin out mucus so people with respiratory illnesses can ...

Ambroxol increased enzyme levels in Parkinson’s dementia patients, but showed no cognitive benefit in a year-long trial.

In a small clinical trial in Canada, a medicine commonly found in European cough syrups has shown early signs it might do ...

A safe and affordable treatment to slow the advancement of Parkinson's dementia has emerged – in the form of a commonly ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Ambroxol, a cough medication, may help stabilize the neuropsychiatric symptoms of Parkinson's disease dementia, a new study ...

Researchers at the Lawson Health Research Institute, part of St. Joseph’s Health Care London, are studying Ambroxol, a cough ...

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph's Health Care London, are investigating ...

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson’s disease, GCase levels are often low.

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people ...